tetano
Editor, Senior Moderator
Vaccine
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.07.129 | How to Cite or Link Using DOI
Permissions & Reprints
Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003?2010
Young June ChoeCorresponding Author Contact Information, a, E-mail The Corresponding Author, Heeyeon Choa, Sung Nam Kima, Geun-Ryang Baea and Jong-Koo Leea
a Division of Vaccine Preventable Disease Control and National Immunization Program, Korea Centers for Disease Control and Prevention, Seoul, Republic of Korea
Received 25 May 2011;
revised 27 July 2011;
accepted 27 July 2011.
Available online 7 August 2011.
Abstract
Background
Vaccination is very important for the control and prevention of influenza, yet no vaccine is perfectly safe. Little is known, however, about influenza vaccination-associated serious adverse events following immunization (AEFI). This study aimed to identify background information on influenza vaccination-related serious AEFI in Korea.
Methods
Retrospective review of data from Korea National Vaccine Injury Compensation Program from 2003 to 2010.
Results
Distribution of approximately 75 million doses of influenza vaccine by end of 2010 gave rise to 42 potentially serious AEFI. In all, nine Guillain-Barr? syndrome, eighteen other neurologic events, eight local events, and seven miscellaneous events were included. 62% of these events were identified to have unlike causal association with the vaccine. The reporting rate of serious AEFI ranged from 0.006 to 0.07 cases per 100,000 distributed doses of the vaccine.
Conclusion
GBS was the most common influenza vaccination-related serious AEFI. Enhancing post-vaccination GBS surveillance may increase public confidence in future routine and pandemic influenza vaccination.
Highlights
► Distribution of approximately 75 million doses of influenza vaccine by end of 2010 gave rise to 42 potentially serious AEFI. ► Nine Guillain-Barr? syndrome, eighteen other neurologic events, eight local events, and seven miscellaneous events were included. ► The reporting rate of serious AEFI ranged from 0.006 to 0.07 cases per 100,000 distributed doses of the vaccine. ► GBS was the most common influenza vaccination-related serious AEFI.
http://www.sciencedirect.com/science/article/pii/S0264410X11011790
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.07.129 | How to Cite or Link Using DOI
Permissions & Reprints
Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003?2010
Young June ChoeCorresponding Author Contact Information, a, E-mail The Corresponding Author, Heeyeon Choa, Sung Nam Kima, Geun-Ryang Baea and Jong-Koo Leea
a Division of Vaccine Preventable Disease Control and National Immunization Program, Korea Centers for Disease Control and Prevention, Seoul, Republic of Korea
Received 25 May 2011;
revised 27 July 2011;
accepted 27 July 2011.
Available online 7 August 2011.
Abstract
Background
Vaccination is very important for the control and prevention of influenza, yet no vaccine is perfectly safe. Little is known, however, about influenza vaccination-associated serious adverse events following immunization (AEFI). This study aimed to identify background information on influenza vaccination-related serious AEFI in Korea.
Methods
Retrospective review of data from Korea National Vaccine Injury Compensation Program from 2003 to 2010.
Results
Distribution of approximately 75 million doses of influenza vaccine by end of 2010 gave rise to 42 potentially serious AEFI. In all, nine Guillain-Barr? syndrome, eighteen other neurologic events, eight local events, and seven miscellaneous events were included. 62% of these events were identified to have unlike causal association with the vaccine. The reporting rate of serious AEFI ranged from 0.006 to 0.07 cases per 100,000 distributed doses of the vaccine.
Conclusion
GBS was the most common influenza vaccination-related serious AEFI. Enhancing post-vaccination GBS surveillance may increase public confidence in future routine and pandemic influenza vaccination.
Highlights
► Distribution of approximately 75 million doses of influenza vaccine by end of 2010 gave rise to 42 potentially serious AEFI. ► Nine Guillain-Barr? syndrome, eighteen other neurologic events, eight local events, and seven miscellaneous events were included. ► The reporting rate of serious AEFI ranged from 0.006 to 0.07 cases per 100,000 distributed doses of the vaccine. ► GBS was the most common influenza vaccination-related serious AEFI.
http://www.sciencedirect.com/science/article/pii/S0264410X11011790